Genomic Health (GHDX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Price: $63.44 --0%
Financial Fact:
Income tax expense: 464K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Income tax expense: 464K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Genomic Health (NASDAQ: GHDX) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $82 million versus the consensus estimate of $81.27 million.
GUIDANCE:
Genomic Health sees FY2016 EPS of ($0.37)-($0.55), versus the consensus of ($0.45). Genomic Health sees FY2016 revenue of $325-335 million, versus prior guidance of $320-335 million and the consensus of $330.5 million.
For earnings history and earnings-related data on Genomic Health (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
